Your session is about to expire
← Back to Search
ATH434 for Multiple System Atrophy
Study Summary
This trialwill test if a new drug, ATH434, is safe and effective for treating Multiple System Atrophy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I often fall or choke due to my advanced disease.I have coordination issues or stiffness and weakness in my limbs.I do not have any unstable medical or mental health conditions.I show symptoms similar to Parkinson's disease.My tests show MSA markers in my body fluids and on my MRI.I have coordination issues or muscle weakness.I experience dizziness when standing up or have bladder control issues.My tests show signs of MSA in my body fluids and MRI.I cannot undergo MRI or lumbar puncture due to health reasons.I have had motor symptoms for more than 4 years.I have a significant neurological condition, but it's not MSA.You have a physical abnormality in your brain as seen on an MRI.I can walk on my own.I show symptoms similar to Parkinson's disease.I experience sudden drops in blood pressure when standing or have bladder issues.
- Group 1: ATH434 Arm 1
- Group 2: ATH434 Arm 2
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies available for participants in this investigation?
"The latest records on clinicaltrials.gov indicate that this trial is still in its recruitment phase, having been initially listed on July 1st 2022 and last updated January 10th 2023."
Does this trial extend eligibility to elderly individuals?
"This study is only open to patients aged 30-75 and does not provide such opportunities for those under 18 or over 65. However, 45 studies are available for minors and 148 projects are accessible to seniors."
Has the ATH434 Arm 1 treatment been approved by the Food and Drug Administration?
"Based on the available data, ATH434 Arm 1 is believed to possess a degree of safety rated at 2. This assessment was made due to this being a Phase 2 trial with some evidence that suggests its security but no proof of efficacy."
What is the current capacity of this experiment in terms of participant numbers?
"Affirmative. The clinical trial database on clinicialtrials.gov reveals that this research is currently recruiting participants, having been first posted on July 1st 2022 and updated as recently as January 10th 2023. 60 patients are being sought after from a single location to partake in the study."
What qualifications must individuals meet to participate in this investigation?
"This clinical study is recruiting 60 patients between the ages of 30 and 75 who have been diagnosed with multiple system atrophy. In order to be eligible, participants need to display parkinsonian features, orthostatic hypotension or bladder dysfunction as well as evidence of ataxia and/or pyramidal signs upon neurological examination; they must also retain their ambulatory capabilities while displaying biomarkers indicative of MSA in both biologic fluid samples and MRI scans."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger